125: GP2: A Global Roadmap for Parkinson’s Genetics

Blauwendraat C et al., The American Journal of Human Genetics - This episode reviews a perspective on the Global Parkinson’s Genetics Program (GP2), a coordinated international effort to expand Parkinson disease genetic discovery across underrepresented populations by combining large-scale genotyping, sequencing, capacity building, and open data sharing. Key terms: Parkinson's disease, genetics, global collaboration, diversity, data sharing.

Study Highlights:
GP2 is a five-year international initiative that aims to generate and harmonize genetic data from a global cohort, prioritizing underrepresented populations and equitable collaboration. The program works with 275 sites and reports data and samples from 265,000 subjects committed to GP2 as of May 2025, with ~83,000 individuals included in a recent data release. Key components include centralized data generation, cloud-based harmonized analysis, extensive training (250+ trainees and many courses), and regional capacity-building such as biorepositories. Lessons learned emphasize stable long-term funding, balancing centralized efficiency with decentralized equity, addressing legal and operational complexity, and promoting transparent, democratized access to data.

Conclusion:
GP2 demonstrates that large-scale, globally inclusive genetics efforts can accelerate discovery, refine biological definitions of Parkinson disease, and enable precision therapeutic strategies; sustained funding, capacity building, and transparent data sharing are critical to its success.

Music:
Enjoy the music based on this article at the end of the episode.

Article title:
Tackling a disease on a global scale, the Global Parkinson’s Genetics Program, GP2: A new generation of opportunities

First author:
Blauwendraat C

Journal:
The American Journal of Human Genetics

DOI:
10.1016/j.ajhg.2025.07.014

Reference:
Blauwendraat C., Noyce A.J., Mata I.F., et al., Tackling a disease on a global scale, the Global Parkinson’s Genetics Program, GP2: A new generation of opportunities. The American Journal of Human Genetics (2025). https://doi.org/10.1016/j.ajhg.2025.07.014

License:
This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) – https://creativecommons.org/licenses/by/4.0/

Support:
Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00

Official website https://basebybase.com

On PaperCast Base by Base you'll discover the latest in genomics, functional genomics, structural genomics, and proteomics.

Episode link: https://basebybase.com/episodes/tackling-a-disease-on-a-global-scale-the-global-parkinsons-genetics-program-gp2-a-new-generation-of-opportunities

QC:
This episode was checked against the original article PDF and publication metadata for the episode release published on 2025-09-02.

QC Scope:
- article metadata and core scientific claims from the narration
- excludes analogies, intro/outro, and music
- transcript coverage: Audited transcript sections covering GP2 goals and structure, pillars, data sharing model, key genetic findings (including RS3115534G in GBA1), pleomorphic risk loci, biomarker context (alpha-synuclein SAA), governance/no-surprises policy, training, and future directions.
- transcript topics: Global diversity and PD genetics need; GP2 structure and four actionable areas; Data democratization and cloud analysis; Training and capacity building; Key genetic findings and pleomorphic risk loci; Biomarkers and alpha-synuclein SAA

QC Summary:
- factual score: 10/10
- metadata score: 10/10
- supported core claims: 6
- claims flagged for review: 0
- metadata checks passed: 4
- metadata issues found: 0

Metadata Audited:
- article_doi
- article_title
- article_journal
- license

Factual Items Audited:
- GP2 consists of 275 research groups across >60 countries.
- Data and samples from 265,000 subjects committed to GP2 as of May 2025.
- 83,000 individuals in GP2 data release 10.
- GP2 pillars: global collaboration and capacity building; democratizing data; growing next generation leaders; applying transformative genetic methods.
- No-surprises policy with a Project Proposal Working Group guiding cross-cohort analysis.
- African-ancestry risk factor RS3115534G disrupts an intronic branch point in GBA1, enabling GBA1-based clinical trials.

QC result: Pass.